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APOBEC3B is one of seven human APOBEC3 DNA cytosine deaminases that function to inhibit the
replication and persistence of retroelements and retroviruses. Human APOBEC3B restricts the replication
of HIV-1 in HEK293 cells, while our laboratory clone of rhesus macaque APOBEC3B did not. We mapped
the restriction determinant to a single amino acid difference that alters enzymatic activity. Human
APOBEC3B D316 is catalytically active and capable of restricting HIV-1 while rhesus APOBEC3B N316 is
not; swapping these residues alters the activity and restriction phenotypes respectively. Genotyping of
primate center rhesus macaques revealed uniform homozygosity for aspartate at position 316.
Considering the C-to-T nature of the underlying mutation, we suspect that our rhesus APOBEC3B cDNA
was inactivated by its own gene product during subcloning in Escherichia coli. This region has been
previously characterized for its role in substrate speciﬁcity, but these data indicate it also has a
fundamental role in deaminase activity.
& 2013 Elsevier Inc. All rights reserved.Introduction
The human APOBEC3 proteins are a family of seven (APOBEC3A, B,
C, D, F, G, and H) single-stranded DNA cytosine deaminases that
function to protect the genome from parasitic genetic elements such
as retroelements, retroviruses, and other forms of foreign DNA.
APOBEC3A and APOBEC3B inhibit the replication and persistence of
foreign DNA and endogenous retroelements, such as LINE-1 and Alu
elements (Bogerd et al., 2006a, 2006b; Bulliard et al., 2011; Chen et al.,
2006; Esnault et al., 2008; Muckenfuss et al., 2006; Stenglein et al.,
2010; Stenglein and Harris, 2006; Wissing et al., 2011). APOBEC3D,
APOBEC3F, APOBEC3G, and APOBEC3H, on the other hand, inhibit the
replication of retroviruses, such as HIV-1 (hereafter HIV), by incorpor-
ating into budding virions and catalyzing cytosine-to-uracil (C-to-U)
mutations in the minus-strand DNA during reverse transcription
(most recently (Hultquist et al., 2011; Refsland et al., 2012); reviewed
by Harris et al. (2012), Malim and Emerman (2008)).
Consistent with a role in innate immune defense, the APOBEC3
locus has undergone sustained expansion during the evolutionary
radiation of the mammalian lineage and most APOBEC3 proteins
show evidence for positive selection (Conticello et al., 2005;ll rights reserved.
Department of Biochemistry,
et S.E., 6-155 Jackson Hall,Duggal et al., 2011; LaRue et al., 2009, 2008; Münk et al., 2012;
Sawyer et al., 2004; Zhang and Webb, 2004). While mice have a
single APOBEC3 gene, humans, chimpanzees, and rhesus macaques
each have seven of similar domain architecture (Conticello et al.,
2005; Hultquist et al., 2011; LaRue et al., 2009, 2008; Schmitt et al.,
2011). Comparative analysis between different APOBEC3 family
members and their homologs has thus been a powerful tool for
mapping determinants of cellular localization, enzymatic activity,
and protein-protein interactions (Albin et al., 2010; Bogerd et al.,
2004; Dang et al., 2011; Lackey et al., 2012; Xu et al., 2004; Zhen
et al., 2009). For example, comparative studies between the
human and African Green monkey APOBEC3G proteins identiﬁed
D128 as an important residue for interaction with the HIV Vif
protein, an essential viral protein for neutralization of the APO-
BEC3 host defense (Bogerd et al., 2004; Mangeat et al., 2004;
Schrofelbauer et al., 2004; Xu et al., 2004).
A recent study of the seven-member human and rhesus
macaque APOBEC3 protein families reported that each rhesus
APOBEC3 protein behaved similarly to its human homolog in HIV
single cycle and spreading infection assays with the exception of
APOBEC3B (Hultquist et al., 2011). While human APOBEC3B
inhibited viral replication in HEK293T single cycle assays, rhesus
APOBEC3B did not (Hultquist et al., 2011). Although this reﬂects
prior reports indicating that human APOBEC3B is capable
of restricting HIV (Bishop et al., 2004; Bogerd et al., 2007,
2006a, 2006b; Doehle et al., 2005; Hakata and Landau, 2006;
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with prior work demonstrating the capacity of rhesus APOBEC3B to
restrict HIV in single cycle assays (Virgen and Hatziioannou, 2007).
To resolve this contradiction, we ﬁrst used a series of comparative
analyses to map the determinant for HIV restriction in human versus
rhesus APOBEC3B. Taking advantage of the distinct antiviral pheno-
types of our human and rhesus APOBEC3B laboratory clones, we
constructed a series of chimeric proteins and single amino acid
substitution mutants and tested them for antiviral and enzymatic
activity using HIV single cycle and oligonucleotide cleavage deaminase
assays, respectively. We found that a single amino acid in loop 7 of the
C-terminal domain, D316, is essential for human APOBEC3B enzymatic
and antiviral activity. Swapping this aspartic acid in human APOBEC3B
for an asparagine, as in our rhesus APOBEC3B clone, completely ablates
enzymatic activity and HIV restriction capacity. The corresponding
N316D substitution, likewise, imparts rhesus APOBEC3B full enzymatic
and antiviral activity. To determine if rhesus APOBEC3B naturally
encodes an aspartic acid or asparagine at position 316, we genotyped
a set of primate center rhesus macaques across this region. While
these analyses revealed several nearby polymorphisms that may
inﬂuence the activity and sequence speciﬁcity of rhesus APOBEC3B,
all individuals were homozygous for D316. Thus, we infer our rhesus
APOBEC3B D316N substitution arose during subcloning, quite possibly
through the action of its own gene product. Thus, these results indicate
that naturally occurring rhesus APOBEC3B (D316) is capable of HIV
restriction in HEK293 cells and identify a previously unappreciated
determinant for APOBEC3 intrinsic enzymatic and antiviral activity.Results
APOBEC3B chimeras map the restriction determinant to the
C-terminal domain
Clustal alignment of the human and rhesus macaque APOBEC3B
protein sequences (derived from NM_004900 and NM_001246230,
respectively) identiﬁed a total of 55 amino acid differences between
the homologs. To ﬁrst narrow in on the region responsible for the
difference in restriction capacity, we created chimeric proteinsFig. 1. HIV-1 restriction potential maps to the human APOBEC3B C-terminal domain. (A)
APOBEC3B, or the human-rhesus/rhesus-human chimeras. A constant amount of Vif-deﬁc
increasing gradient of the indicated APOBEC3B vector. Percent infectivity of HIV-1IIIB is m
mean of the two technical replicates ± standard deviation. Representative immunoblots
by those cells are shownwith their respective tubulin (TUB) and p24 (CA) loading contro
HIV-1 restriction potential. HIV-1 single cycle assays were performed with each chimera
to the human or rhesus APOBEC3B parent, respectively. An alignment of human (top
determinant mapped is shown above. Differences between the human and rhesus seque
interpretation of the references to color in this ﬁgure legend, the reader is referred to tbetween the human and rhesus APOBEC3B N-terminal and
C-terminal domains. Human and rhesus APOBEC3B are each com-
posed of two zinc-coordinating domains deﬁned by a characteristic
H-x-E-x25–31-C-x2−4-C motif (Conticello et al., 2005; Hultquist et al.,
2011; Virgen and Hatziioannou, 2007). While the N-terminal
domain of double-domain APOBEC3 proteins is thought to be
important for nucleic acid binding, the C-terminal domain contains
the active catalytic site (Haché et al., 2005; Hakata and Landau,
2006; Jónsson et al., 2006; Navarro et al., 2005; Stenglein and
Harris, 2006). Human and rhesus APOBEC3B were then tested for
HIV antiviral activity alongside these domain chimeras in a single-
cycle infectivity assay. Increasing amounts of each protein were
expressed alongside a constant amount of Vif-deﬁcient HIV proviral
plasmid. Virions produced from these cells were collected and used
to infect a CEM-GFP reporter line to determine infectivity (Gervaix
et al., 1997). Cell and viral-like particle (VLP) lysates were simulta-
neously collected and used for immunoblotting to detect protein
expression and incorporation into viral particles. Supernatants from
cells expressing only APOBEC3B (no virus) were concentrated in
parallel as a negative control for virus-speciﬁc packaging and
yielded no APOBEC3B by immunoblot (data not shown).
In the absence of APOBEC3B, viral infectivity is high (normal-
ized to 100%, Fig. 1A). As an increasing amount of human
APOBEC3B is expressed in the producer cells, more is packaged
into the viral particles and infectivity rapidly decreases (Fig. 1A).
Infectivity was not normalized to account for differences in virus
release, so this decrease reﬂects the ability of APOBEC3B to elicit
both foreign DNA and HIV restriction (Stenglein et al., 2010). The
highest levels of human APOBEC3B expression reduced infectivity
by greater than 90%, whereas even the highest levels of rhesus
APOBEC3B expression failed to reduce infectivity below approxi-
mately 50% (Fig. 1A). The hu-rhAPOBEC3B (human N-terminal
domain and rhesus C-terminal domain) chimera behaves pheno-
typically similar to the rhesus protein, while the rh-huAPOBEC3B
(rhesus N-terminal domain and human C-terminal domain) chi-
mera phenocopies the human protein. Each protein was expressed
and packaged into the viral particles at roughly equivalent levels
(Fig. 1A). These results indicate that the restriction determinant
tracks with the C-terminal domain of human APOBEC3B.HIV-1 infectivity in the presence of increasing amounts of human APOBEC3B, rhesus
ient A200C HIV-1IIIB molecular clone was co-transfected into HEK293T cells with an
easured by infection of CEM-GFP in duplicate and ﬂow cytometry, reported as the
of HA-tagged APOBEC3B proteins (HA) in cell lysates and HIV-1 particles produced
ls. (B) Schematic of human/rhesus APOBEC3B C-terminal domain chimeras and their
as in (A) and found to be restrictive or non-restrictive depending on their similarity
) and rhesus (bottom) APOBEC3B amino acid sequences to which the restriction
nces are highlighted in gray and the catalytic glutamate is highlighted in green. (For
he web version of this article.)
Fig. 2. HIV-1 restriction potential tracks with the putative alpha 4 helix region of
human APOBEC3B. HIV-1 infectivity in the presence of increasing amounts of
human APOBEC3B, rhesus APOBEC3B, or various human-rhesus alpha helix
chimeras in the C-terminal domain. A constant amount of Vif-deﬁcient A200C
HIV-1IIIB molecular clone was co-transfected into HEK293T cells with an increasing
gradient of the indicated APOBEC3B vector. Percent infectivity of HIV-1IIIB is
measured by infection of CEM-GFP in duplicate and ﬂow cytometry, reported as
the mean of the two technical replicates±standard deviation. Representative
immunoblots of HA-tagged APOBEC3B proteins (HA) in cell lysates and HIV-1
particles produced by those cells are shownwith their respective tubulin (TUB) and
p24 (CA) loading controls.
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proteins within the APOBEC3B C-terminal domain and tested them
for antiviral activity. Chimeras that restricted infectivity of Vif-
deﬁcient HIV at a level similar to human APOBEC3B were deemed
restrictive, while chimeras with restriction potential similar to
rhesus APOBEC3B were considered non-restrictive (Fig. 1B). Chi-
mera 1, containing rhesus amino acid residues 1–223 and human
residues 224–382, remained restrictive while chimera 3, contain-
ing rhesus 1–333 and human 334–382, lacked restriction capacity
(Fig. 1B). The reciprocal chimeras had opposite antiviral pheno-
types (Fig. 1B). These results implicate human APOBEC3B residues
224–333 as important for restriction. Based on the homologous
APOBEC3G C-terminal domain crystal structure (PDB: 3IR2,
(Shandilya et al., 2010)), this region includes three predicted
surface helices, alpha 2 through alpha 4.
Human APOBEC3B D316 is an important determinant
of antiviral activity
Human and rhesus APOBEC3B differ in 20 amino acids between
residues 224 and 333. Most of these differences cluster either near
the active site or along the alpha 2, 3, and 4 helices (differences
highlighted in gray, catalytic glutamate in green, Fig. 1B). We
tested many of these amino acid differences for their impact on
antiviral activity by changing the residues in human APOBEC3B to
the corresponding residue in rhesus APOBEC3B. Many of these
single or clustered amino acid changes (L230P, E241Q, L245V/
L246P/C247R/F249D, R252C, R257C, R252C/R257C, L261Q, P263S,
I272T, M325T, C354R) had no impact on antiviral activity or
packaging in single-cycle assays (data not shown).
Many of the amino acid differences occur in clusters along
alpha helices 2, 3, and 4 of the C-terminal domain. To see if the
helices held the responsible determinant, we targeted clustered
changes in the alpha helix 2 (R257C/L261Q/P263S/L265W), alpha
helix 3 (G291D/E292Q/R294Y), and alpha helix 4 (D316N/K320Q/
Q324R/M325T) regions. While human APOBEC3B, the human
APOBEC3B alpha 2 chimera, and the human ABOPEC3B alpha
3 chimera all exhibited strong antiviral activity, the human
APOBEC3B alpha 4 chimera showed a greatly diminished activity
similar to that of rhesus APOBEC3B (Fig. 2). All human APOBEC3B
constructs in which the alpha 4 helix region was altered to match
the rhesus residues exhibited the same diminished activity,
demonstrating a dominant effect of the alpha 4 substitutions on
restriction activity (Fig. 2). The human APOBEC3B alpha 3 substitu-
tions alone also yielded slightly reduced HIV restriction capacity,
but this is likely due to lower expression levels of this protein. This
reduced activity is not reproduced in the alpha2/alpha3 construct
(Fig. 2). All of the above APOBEC3B helix chimeras incorporate into
viral particles at roughly equal efﬁciencies.
To deﬁne the speciﬁc amino acid change(s) responsible for the
loss of restriction capacity in the human APOBEC3B alpha 4 chi-
mera construct, we introduced each substitution singly (D316N,
K320Q, or Q324R). Human APOBEC3B M325T was found to have
no effect in our initial site-directed mutagenesis screen and so was
not included here. Human APOBEC3B and the K320Q and Q324R
constructs strongly restricted HIV replication, while human APO-
BEC3B D316N exhibited a dramatic loss of antiviral activity
(Fig. 3A). All proteins were expressed and incorporated into viral
particles equivalently. The corresponding rhesus-to-human amino
acid substitutions were created in rhesus APOBEC3B to conﬁrm the
effect of residue 316. Rhesus APOBEC3B lacks strong antiviral
activity, but substituting in the human alpha 4 region (N316D/
Q320K/R324Q/T325M) or the N316D substitution alone greatly
enhanced antiviral activity (Fig. 3A). Thus, an aspartic acid at
residue 316 is necessary for antiviral activity in human and rhesus
APOBEC3B.D316 is required for the deaminase activity of APOBEC3B
To determine if the D316N substitution impacts APOBEC3B
deaminase activity, we conducted an oligonucleotide cleavage
assay in which a ﬂuorescently labeled oligonucleotide containing
the preferred 5′-TC-3′ APOBEC3B deamination target sequence is
incubated with whole cell lysate containing the indicated APO-
BEC3 protein (Burns et al., 2013). After APOBEC3-mediated cyto-
sine deamination, uracil is removed with uracil DNA glycosylase,
and the phosphodiester backbone is cleaved at the abasic site by
treatment with sodium hydroxide. Human APOBEC3A is a potent
DNA deaminase with similar sequence speciﬁcity to APOBEC3B,
and results in full deamination of the substrate and complete
cleavage to product (Fig. 3B and (Carpenter et al., 2012; Love et al.,
2012; Stenglein et al., 2010; Thielen et al., 2010; Wijesinghe and
Bhagwat, 2012)). Human APOBEC3B likewise resulted in nearly
full oligo cleavage. HEK293T lysate alone, the APOBEC3A E72A
catalytic mutant, and the APOBEC3B E255Q catalytic mutant
exhibited no deaminase activity. All human APOBEC3B constructs
with an aspartic acid at position 316, including the alpha 2 chimera,
alpha 3 chimera, K320Q, and Q324R, were all able to efﬁciently
deaminate the substrate, resulting in near complete cleavage
(Fig. 3B). However, all human APOBEC3B constructs with an
asparagine residue at position 316, including the alpha 4 chimera
and D316N, were inactive, comparable to the catalytic mutant. All
rhesus APOBEC3B constructs were likewise inactive with the
exception of N316D, which elicited strong deaminase activity
(Fig. 3B).
To control for the possibility that one or more of these
substitutions could have changed the substrate speciﬁcity of
human or rhesus APOBEC3B, this assay was repeated using a
5′-TCC-3′ ﬂuorescently labeled oligonucleotide (data not shown).
As before, all APOBEC3B constructs with an aspartic acid at
position 316, including human APOBEC3B and rhesus APOBEC3B
N316D, were all able to efﬁciently deaminate the substrate.
Conversely, all APOBEC3B constructs with an asparagine residue
at position 316, including rhesus APOBEC3B and human APOBEC3B
Fig. 4. Conservation and predicted structural context of APOBEC3B D316. (A) Amino acid
and their related family members. Blue residues indicate perfect conservation. APOBEC3
(asparagine). (B) Predicted structure of human APOBEC3B C-terminal domain based on
highlighted in red in close proximity to the catalytic E255 in green. (For interpretation of
of this article.)
Fig. 3. An aspartic acid at APOBEC3B residue 316 is crucial for HIV-1 restriction and
deaminase activity. (A) HIV-1 infectivity in the presence of increasing amounts of
human APOBEC3B, rhesus APOBEC3B, or various helix or single amino acid
substitution constructs. A constant amount of Vif-deﬁcient A200C HIV-1IIIB molecular
clone was co-transfected into HEK293T cells with an increasing gradient of the
indicated APOBEC3B vector. Percent infectivity of HIV-1IIIB is measured by infection
of CEM-GFP in duplicate and ﬂow cytometry, reported as the mean of the two
technical replicates ± standard deviation. Representative immunoblots of HA-tagged
APOBEC3B proteins (HA) in cell lysates and HIV-1 particles produced by those cells
are shown with their respective tubulin (TUB) and p24 (CA) loading controls.
(B) Deaminase activity of human APOBEC3B, rhesus APOBEC3B, or various helix or
single amino acid substitution constructs in cell lysates as measured by an oligo
cleavage assay. A constant amount of each indicated APOBEC3 expression construct
was transfected into HEK293T cells and lysates collected for oligo cleavage (top) or
immunoblotting (bottom). Deaminase activity is indicated by cleavage of the oligo
substrate to a smaller product. Expression of each deaminase was veriﬁed by
immunoblotting for each of the HA-tagged APOBEC3 proteins as shown below.
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acid at position 316 is an important determinant for the intrinsic
DNA deaminase activity of APOBEC3B.
Genotyping of rhesus APOBEC3B exon 6 reveals several
polymorphic residues
Phylogenetic comparisons of several catalytic human and
rhesus APOBEC3 deaminase domains indicate conservation of an
aspartic acid residue at position 316 with the exception of the
APOBEC3G homologs and, notably, our rhesus APOBEC3B clone
(Fig. 4A). Structural modeling of the human APOBEC3B C-terminal
domain positions residue 316 in close proximity to the catalytic
glutamate, suggesting it may be important for substrate binding or
local active site architecture (Fig. 4B). In contrast to the rhesus
APOBEC3B mRNA sequence in Genbank (NM_001246230), the
APOBEC3B gene in the rhesus genome assembly indicates an
aspartic acid at residue 316 as does at least one prior report of
APOBEC3B cDNA from rhesus macaque PBMCs (assembly
AANU00000000.1 and (Virgen and Hatziioannou, 2007)). Taken
together with the fact that APOBEC3 proteins are under positive
selection and therefore have extensive variation within species, it
is possible that this residue is polymorphic within the natural
population. However, it is also possible that the D316N substitu-
tion emerged during our initial subcloning of rhesus APOBEC3B.
Mutation of a GAC (aspartic acid) to an AAC (asparagine) codon
could be catalyzed by APOBEC3B expression in E. coli, resulting in a
less toxic and therefore self-selecting mutant.
To determine if rhesus APOBEC3B is naturally polymorphic at
position 316, we sequenced a portion of exon 6 in genomic DNA
isolated from 45 independent rhesus macaques. While we found
extensive variation in this region and identiﬁed six polymorphic
residues, all individuals were homozygous for alleles encoding an
aspartic acid at position 316 (Fig. 5). It should be noted that all
genomic DNA samples were collected from primates in captivity,
and that these polymorphism frequencies may not be representa-
tive of frequencies in the wild. Nevertheless, we consider it
unlikely that N316 is a naturally occurring variant and, therefore,
believe it to be the result of a mutation that arose during
subcloning in E. coli.Discussion
We used a series of comparative analyses to map the determi-
nant for HIV restriction present in human APOBEC3B, but not insequence alignment of the predicted loop 7 regions of human and rhesus APOBEC3B
B residue 316 and its predicted homologs are bolded in black (aspartic acid) or red
the human APOBEC3G C-terminal domain crystal structure (PDB: 3IR2). D316 is
the references to color in this ﬁgure legend, the reader is referred to the web version
Fig. 5. Naturally occurring APOBEC3B variants in rhesus macaques. An amino acid
alignment displaying a portion of rhesus APOBEC3B near residue 316 and
polymorphisms observed among 45 individual rhesus macaques. A dash ‘–'
indicates that all animals surveyed were homozygous for alleles encoding the
residue in the above consensus. At positions in red, some individuals were
homozygous for alleles encoding alternate amino acids, as indicated. An ‘X’
indicates that the individual is heterozygous for alleles encoding the two possible
amino acids observed at this site. The numbers of individuals found to have each of
the indicated genotypes are indicated to the right. A schematic of the predicted
structural motifs based on the human APOBEC3G C-terminal domain crystal
structure is depicted above (PDB: 3IR2). (For interpretation of the references to
color in this ﬁgure legend, the reader is referred to the web version of this article.)
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the antiviral activity of APOBEC3B chimeras and single amino
acid substitution mutants, we identiﬁed a single residue, D316,
necessary for the HIV restriction capacity of APOBEC3B. Swapping
this residue for the corresponding N316 of our rhesus APOBEC3B
clone rendered human APOBEC3B inactive in both single cycle and
oligonucleotide cleavage assays. Conversely, rhesus APOBEC3B
N316D displayed full catalytic activity and HIV restriction capacity.
Genotyping of primate center rhesus macaques yielded uniform
homozygosity for an aspartic acid at position 316, making it likely
that our N316 mutant arose during subcloning ex vivo. While the
presence of N316 could not be veriﬁed as naturally occurring
variant in rhesus APOBEC3B, these results implicate residue 316 as
a key determinant of enzymatic and antiviral activity. Further-
more, the existence of multiple polymorphisms in this region may
indicate naturally circulating rhesus APOBEC3B variants with
altered activities or substrate speciﬁcities.
Residue 316 is predicted to be in the loop 7 region of the
APOBEC3B C-terminal domain between beta-strand 4 and alpha-
helix 4 (Fig. 4B). This region has been the focus of several other
studies seeking to map determinants in the APOBEC3 proteins.
A comparison of human APOBEC3D and APOBEC3F revealed a key
determinant for HIV restriction in the same loop 7 region of the
C-terminal domain of APOBEC3F. When cysteine 320 of APOBEC3D
was swapped for the corresponding tyrosine residue of APOBEC3F,
antiviral activity of APOBEC3D was enhanced several fold (Dang
et al., 2011). This same loop region has also been studied for its
role in substrate speciﬁcity and DNA binding (Carpenter et al.,
2010; Kohli et al., 2009; Rausch et al., 2009; Wang et al., 2010).
Chimeric AID/APOBEC3G proteins in which loop 7 of APOBEC3G
and the corresponding region of AID were swapped, mirrored the
substrate speciﬁcity of the protein from which the loop region
originated (Carpenter et al., 2010; Kohli et al., 2009; Wang et al.,
2010). Furthermore, a screen of potential APOBEC3G inhibitors
identiﬁed two classes of small molecules that inhibit deaminase
activity by covalently binding APOBEC3G C321, which is also
located within loop 7 (Li et al., 2011; Olson et al., 2013). These
ﬁndings, combined with this study, highlight the broad impor-
tance of this loop region for both APOBEC3 substrate speciﬁcity
and deaminase activity. One possibility is that aspartic acid 316 is
required for substrate binding as it lies directly adjacent to the
predicted nucleic acid binding cleft (Fig. 4B).
Phylogenetic comparison of several catalytic human and rhesus
APOBEC3 deaminase domains indicate conservation of an asparticacid residue at position 316 (Fig. 4A and Fig. 5). Our attempts failed
to verify the presence of N316 as a naturally occurring variant
within the rhesus population. While these results do not rule out
the possibility that residue 316 is polymorphic, we believe that the
D316N substitution emerged during our initial cloning as such a
mutant would undoubtedly be less toxic to E. coli. This and other
experiences in our laboratory have since justiﬁed the inclusion of
an intron in all APOBEC3A and APOBEC3B expression constructs to
ensure safe propagation in bacteria. In independent work several
years ago, a similar human APOBEC3B mutant was identiﬁed
during attempts to clone the human APOBEC3B cDNA (W228L
and D316N (Stenglein and Harris, 2006)). We must update our
prior ﬁndings, therefore, to report that naturally occurring rhesus
APOBEC3B D316 can restrict HIV-1 in HEK293T cells.
While N316 was not veriﬁed as a naturally occurring poly-
morphism in rhesus APOBEC3B, our results indicated the occur-
rence of six other polymorphic residues nearby (Fig. 5). As all these
residues lie in a region shown to be important for enzyme activity
and substrate speciﬁcity, it is possible that there are naturally
occurring variants that differ in one or both of these regards. The
existence of naturally occurring variations that inactivate rhesus
APOBEC3B would parallel the documented deletion of APOBEC3B
in certain human populations (Kidd et al., 2007). Such a scenario
would strongly implicate a high cost-to-beneﬁt ratio for the
maintenance of APOBEC3B. The strong DNA deamination activity
and nuclear localization of APOBEC3B may combine to present a
signiﬁcant risk to genomic integrity (e.g. (Burns et al., 2013)).
While the possible risks of maintaining an active APOBEC3B
allele are clear, the physiologic role of APOBEC3B remains ambig-
uous. While several studies have demonstrated the capacity for
APOBEC3B to restrict HIV in HEK293T based single cycle assays
(Bishop et al., 2004; Bogerd et al., 2007, 2006a, 2006b; Doehle
et al., 2005; Hakata and Landau, 2006; Kinomoto et al., 2007; Rose
et al., 2005; Virgen and Hatziioannou, 2007; Yu et al., 2004),
neither human nor rhesus APOBEC3B are appreciably expressed in
human or rhesus CD4þ T lymphocytes and neither are capable of
packaging into or inhibiting the replication of HIV when expressed
stably in T cells (Haché et al., 2008; Hultquist et al., 2011; Refsland
et al., 2010; Schmitt et al., 2011). Furthermore, human APOBEC3B is
not targeted for degradation by HIV Vif (Bishop et al., 2004; Doehle
et al., 2005; Hultquist et al., 2011; Rose et al., 2005; Yu et al., 2004),
though rhesus APOBEC3B is partially sensitive to degradation by
SIVmac239 and SIVagm Vif (Hultquist et al., 2011; Virgen and
Hatziioannou, 2007). Therefore, the role of APOBEC3B in retrovirus
restriction remains unclear. Alternate roles in retroelement restric-
tion and foreign DNA restriction have also been proposed (Bogerd
et al., 2006a, 2006b; Chen et al., 2006; Esnault et al., 2008;
Muckenfuss et al., 2006; Stenglein et al., 2010; Stenglein and
Harris, 2006; Wissing et al., 2011). Regardless, the beneﬁt may
not always outweigh the cost of encoding such a potent DNA
mutator, a result that may be reﬂected in the selective loss of
APOBEC3B function in certain primate subpopulations.
In conclusion, we have characterized the restriction determi-
nant that accounts for the distinct antiviral phenotypes previously
observed for human and rhesus APOBEC3B (Hultquist et al., 2011).
While rhesus APOBEC3B N316 may not be a naturally occurring
variant, the data presented here provide new information regard-
ing DNA deaminase domain active site architecture and local
amino acid requirements. Extension of these ﬁndings to the other
APOBEC3 family members will likely aid in the understanding of
the general APOBEC3 deaminase and HIV restriction mechanism
(Haché et al., 2005; Miyagi et al., 2007; Navarro et al., 2005;
Schumacher et al., 2008). Furthermore, identiﬁcation of several
polymorphisms in a region of rhesus APOBEC3B known to play a
role in deaminase activity and substrate speciﬁcity suggest the
existence of naturally occurring functional variants that may shed
R.M. McDougle et al. / Virology 441 (2013) 31–3936further light on the physiologic roles and potential pathological
risks of APOBEC3B.Materials and methods
Expression constructs
The Vif-deﬁcient (X26×27) HIV-1IIIB A200C proviral expression
construct has been reported (Haché et al., 2008). The carboxy(C)-
terminally 3xHA-tagged, human APOBEC3A, intron-containing
human APOBEC3B, and intron-containing rhesus macaque APO-
BEC3A expression constructs have also been reported (Hultquist
et al., 2011). The derivative human APOBEC3A E72A and human
APOBEC3B E255Q catalytic mutants were generated via site-
directed mutagenesis using primers 5′-GGC CGC CAT GCG GCG
CTG CGC TTC TTG-3′/5′-CAA GAA GCG CAG CGC CGC ATG GCG
GCC-3′ and 5′-GCC GCC ATG CGC AGC TGC GCT TC-3′/5′-GAA GCG
CAG CTG CGC ATG GCG GC-3′, respectively.
To match the intron placement in the human APOBEC3B
expression vector, a β-globin intron was inserted into the rhesus
macaque APOBEC3B coding region between exons 5 and 6. The 5′
end and 3′ ends of rhesus APOBEC3B were ampliﬁed from a cDNA
construct previously provided by T. Hatziioannou using primer
pairs 5′-NNN NGG TAC CAC CAT GAA TCC ACA GAT CAG-3′/5′-ATC
TCC TGG ACT CAC CTG GTT GCA TAG AAA-3′ and 5′-CTT TCA TCT
CAA CAG GCT AAG AAT GTT CCC-3′/5′-NNN NGC GGC CGC CCG TTT
CCC TGA TTC TG-3′, respectively. The β-globin intron was ampliﬁed
using primers 5′-GTG AGT CCA GGA GAT GTT TCA GCA CTG TTG
CC-3′ and 5′-CTG TTG AGA TGA AAG GAG ACA ATA AAG ATG AC-3′.
The fragments were gel puriﬁed (GeneJET gel extraction kit;
Fermentas) and connected by overlapping PCR. The full-length,
intron-containing segment was PCR ampliﬁed, gel puriﬁed,
digested with KpnI/NotI, and ligated into the similarly digested
pcDNA3.1(þ) vector with a C-terminal 3xHA tag.
The human-rhesus APOBEC3B domain chimeras were generated
by digestion of the human and rhesus APOBEC3B expression con-
structs described above with BamHI, which cuts once in the intron
and once in the 3′ ﬂanking region within the pcDNA3.1(þ) vector
sequence. The fragment containing part of the intron and exons
6 through 8 of human APOBEC3B was ligated into the similarly
digested rhesus APOBEC3B expression construct and vice versa. The
resultant chimeric expression constructs were sequence veriﬁed.
The other human-rhesus APOBEC3B chimeras were generated by
overlapping PCR between fragments generated from the human
and rhesus expression constructs. For chimeric proteins 1 and 2
(human APOBEC3B residues 1–223 with rhesus APOBEC3B residues
224–382 and vice versa) the N-terminal fragments of human and
rhesus APOBEC3B were PCR ampliﬁed using primers 5′-NNN NAA
GCT TGG TAC CAC CAT GAA TCC ACA GAT CAG-3′/5′-GAC CCA GGT
GCC ATT GTC-3′ and the C-terminal fragments were ampliﬁed using
primers 5′-GAC AAT GGC ACC TGG GTC-3′/5′-GTC GAC GTT TCC CTG
ATT CTG GAG AAT GGC CC-3′. For chimeric proteins 3 and 4 (human
APOBEC3B residues 1–333 with rhesus APOBEC3B residues 334–
382 and vice versa) the amino(N)-terminal fragments of human and
rhesus APOBEC3B were PCR ampliﬁed using primers 5′-NNN NAA
GCT TGG TAC CAC CAT GAA TCC ACA GAT CAG-3′/5′-AGA CTT GGG
CCC CAG CAT C-3′ and the C-terminal fragments were ampliﬁed
using primers 5′-GAT GCT GGG GCC CAA GTC T-3′/5′-GTC GAC GTT
TCC CTG ATT CTG GAG AAT GGC CC-3′. Reciprocal fragments were
stitched together into full-length, intron-containing chimeric com-
plementary (c)DNAs by overlapping PCR. These were gel puriﬁed,
digested with KpnI/NotI, and ligated into a similarly digested
pcDNA3.1(þ) vector with a C-terminal 3xHA tag.
Additional APOBEC3B amino acid substitution constructs were
created using site-directed mutagenesis on the human or rhesusAPOBEC3B expression plasmids. See Table 1 for a full list of constructs
and deoxyoligonucleotide primer sequences used in this study.
Cell lines
Human embryonic kidney (HEK)293T cells were maintained in
Dulbecco's modiﬁed eagle medium (DMEM) supplemented with
10% fetal bovine serum (FBS) and 0.5% penicillin/streptomycin
(P/S). CEM-GFP cells, obtained from the AIDS Research and
Reference Reagent Program, were maintained in Roswell Park
Memorial Institute (RPMI) media containing 10% FBS and 0.5% P/S.
HIV single cycle assay with replication proﬁcient virus
At 50% conﬂuency, HEK293T cells were transfected (TransIt,
Mirus) with 1 µg Vif-deﬁcient (X26×27) HIV-1IIIB A200C proviral
expression construct and either 25, 50, 100, 200, or 400 ng of the
appropriate APOBEC3B-3xHA expression construct. After 48 h, the
virus-containing supernatants were harvested, ﬁlter puriﬁed, and
used to infect the CEM-GFP reporter cell line to quantify infectivity.
Cell and viral particle lysates were collected for immunoblotting.
Immunoblotting
HEK293T cells were pelleted by centrifugation at 8000 rpm for
2min, washed in 1X PBS, and lysed directly in 2.5× Laemmli Sample
Buffer (25 mM Tris pH 6.8, 8% glycerol, 0.8% SDS, 2% 2-mercaptoetha-
nol, 0.02% bromophenol blue). Virus particles from the culture super-
natants were puriﬁed using 0.45 μm PVDF ﬁlters (Millipore), pelleted
by centrifugation at 13,000 rpm for 2 h through a 20% sucrose 1X PBS
buffer, and lysed directly in 2.5× Laemmli Sample Buffer. All samples
were homogenized at 98C for 30 min prior to loading. Samples were
run on 12.5% Tris–HCl SDS-PAGE resolving gels with 4% stacking gels
both with a 37.5 acrylamide:1 bis-acrylamide ratio (BioRad Criterion)
at 90 V for 30 min followed by 150 V for 1 h. Proteins were transferred
to PVDF membranes by methanol-based electrotransfer (BioRad
Criterion Blotter) at 90 V for 2 h. Membranes were blocked in 4% Milk
in 1X PBS with 0.1% Tween-20 overnight. Proteins were detected using
primary antibodies against HA to detect HA-tagged APOBEC3B (HA.11;
Covance), TUB (tubulin; Covance), or p24 (NIH ARRRP 3537 courtesy of
B. Chesebro and K. Wehrly). Anti-mouse horseradish peroxidase
(HRP)-conjugated secondary antibody (Jackson ImmunoResearch)
was detected using Hyglo HRP detection reagents (Denville Scientiﬁc).
Blots were incubated in stripping buffer (1xPBS, 0.2M glycine, 1.0%
SDS, 1.0% Tween-20, pH 2.2) before reprobing.
Flow cytometry
At 48 h post infection, CEM-GFP cells were ﬁxed in 4% paraf-
ormaldehyde in 1× PBS. GFP ﬂuorescence was measured using a
Becton Dickinson FACS Canto II ﬂow cytometer. HIV infectivity was
quantiﬁed by calculating the percent of live cells that were positive
for GFP signal using FlowJo Flow Cytometry Analysis Software
(Version 8.8.6). Data was normalized to the 0 ng APOBEC3B control
as 100% infectivity.
Oligonucleotide cleavage assay
At 50% conﬂuency, HEK293T cells were transfected (TransIt,
Mirus) with 100 ng of the indicated APOBEC3 expression construct.
After 48 h, the cellswerewashedand split into twosamples, onehalf
for immunoblotting and the other for an oligonucleotide cleavage
assay. Transfected cells were resuspended in 1X HED buffer (25 mM
HEPES, 5 mM EDTA, 10% Glycerol, 1mM DTT, proteasome inhibitor,
pH 7.8) and homogenized with three short (5 s) pulses of sonication
(Misonix XL-2000). The deamination reaction was prepared by
Table 1
Deoxyoligonucleotides used in this study for mutagenesis.
Construct Primers
hsAPOBEC3B L230P 5′-ggcacctgggtcccgatggaccagcac-3′
5′-gtgctggtccatcgggacccaggtgcc-3′
hsAPOBEC3B E241Q 5′-ggctttctatgcaaccaggtgagtccaggag-3′
5′-ctcctggactcacctggttgcatagaaagcc-3′
hsAPOBEC3B L245V/L246P/C247R/F249D 5′-cctttcatctcaacaggctaagaatgttccccgtggcgattacggccgccatg-3′
5′-catggcggccgtaatcgccacggggaacattcttagcctgttgagatgaaag-3′
hsAPOBEC3B R252C 5′-gtggcttttacggctgccatgcggagctg-3′
5′-cagctccgcatggcagccgtaaaagccac-3′
hsAPOBEC3B R257C 5′-gccatgcggagctgtgcttcttggacctg-3′
5′-caggtccaagaagcacagctccgcatggc-3′
hsAPOBEC3B R252C/R257C 5′-gtggcttttacggctgccatgcggagctg-3′
5′-cagctccgcatggcagccgtaaaagccac-3′
5′-gccatgcggagctgtgcttcttggacctg-3′
5′-caggtccaagaagcacagctccgcatggc-3′
hsAPOBEC3B L261Q 5′-ctgcgcttcttggaccaggttccttctttgcag-3′
5′-ctgcaaagaaggaacctggtccaagaagcgcag-3′
hsAPOBEC3B P263S 5′-cgcttcttggacctggttagttctttgcagttggacc-3′
5′-ggtccaactgcaaagaactaaccaggtccaagaagcg-3′
hsAPOBEC3B I272T 5′-gacccggcccagacctacagggtcact-3′
5′-agtgaccctgtaggtctgggccgggtc-3′
hsAPOBEC3B M325T 5′-atataaggaggcgctgcaaacgctgcgggatg-3′
5′-catcccgcagcgtttgcagcgcctccttatat-3′
hsAPOBEC3B C354R 5′-gtaccgccagggacgtcccttccagcc-3′
5′-ggctggaagggacgtccctggcggtac-3′
hsAPOBEC3B R257C/L261Q/P263S/L265W 5′-tgcgcttcttggaccaggttagttcttggcagttggacccggc-3′
5′-gccgggtccaactgccaagaactaacctggtccaagaagcgca-3′
5′-gccatgcggagctgtgcttcttggaccag-3′
5′-ctggtccaagaagcacagctccgcatggc-3′
hsAPOBEC3B G291D/E292Q/R294Y 5′-gcttctcctggggctgtgccgatcaggtgtatgcgttccttcaggagaacac-3′
5′-gtgttctcctgaaggaacgcatacacctgatcggcacagccccaggagaagc-3′
hsAPOBEC3B D316N/K320Q/Q324R/M325T 5′-gcccgcatctatgattacaaccccctatatcaggaggcgct-3′
5′-gcatttgcagcgcctcctgatatagggggttgtaatcatagatgcgggc-3′
5′-atatcaggaggcgctgagaacgctgcgggatgctggg-3′
5′-cccagcatcccgcagcgttctcagcgcctcctgatat-3′
hsAPOBEC3B D316N 5′-gctgcccgcatctatgattacaaccccctatataag-3′
5′-cttatatagggggttgtaatcatagatgcgggcagc-3′
hsAPOBEC3B K320Q 5′-tctatgattacgaccccctatatcaggaggcgctgc-3′
5′-gcagcgcctcctgatatagggggtcgtaatcataga-3′
hsAPOBEC3B Q324R 5′-ctatataaggaggcgctgagaatgctgcgggatgctgg-3′
5′-ccagcatcccgcagcattctcagcgcctccttatatag-3′
rhAPOBEC3B N316D/Q320K/R324Q/T325M 5′-ctgcccgcatctatgattacgaccccctgtatcag-3′
5′-ctgatacagggggtcgtaatcatagatgcgggcag-3′
5′-tctatgattacgaccccctgtataaggaggcactgc-3′
5′-gcagtgcctccttatacagggggtcgtaatcataga-3′
5′-ataaggaggcactgcaaatgctgcgggatgctgg-3′
5′-ccagcatcccgcagcatttgcagtgcctccttat-3′
rhAPOBEC3B N316D 5′-ctgcccgcatctatgattacgaccccctgtatcag-3′
5′-ctgatacagggggtcgtaatcatagatgcgggcag-3′
rhAPOBEC3B Q320K 5′-tctatgattacaaccccctgtataaggaggcactgc-3′
5′-gcagtgcctccttatacagggggttgtaatcataga-3′
rhAPOBEC3B R324Q 5′-caggaggcactgcaaacgctgcgggat-3′
5′-atcccgcagcgtttgcagtgcctcctg-3′
R.M. McDougle et al. / Virology 441 (2013) 31–39 37mixing 16.5 μL cleared lysate, 0.25 μL RNaseA (20 Units, QIAgen),
1 μL ﬂuorescein-labelled oligonucleotide (4 pmol, 5′-ATT ATT ATT
ATT CTA ATG GAT TTA TTT ATT TAT TTA TTT ATT T-ﬂuorescein-3′),
2 μL 10× UDG buffer, and 0.25 μL UDG (1.25 Units). After 2 h
incubation at 37 °C, 2 μL of 1.0 M sodium hydroxide were added to
each reaction to induce cleavage at abasic sites. Samplesweremixed
with 2X Formamide Buffer (80% Formamide, 1× TBE, 0.05% Bromo-
phenol blue, 0.01% Xylene cyanol) and run on a 15% Urea-TBE gel.
Fluorescein tagged oligonucleotide products were detected using a
Fugi FLA-5000 scanner.
Sequencing of rhesus APOBEC3B exon 6
Blood samples or transformed B cell lines were obtained from
45 rhesus macaque (Macaca mulatta) individuals housed at either
the Keeling Center for Comparative Medicine and Research (42/45)
or at the New England Primate Research Center (3/45). B cell lineswere expanded in RPMI, 20% FBS, P/S, L-glutamine, HEPES, and
AZT. Genomic DNA from blood and B cells was isolated using the
All Prep DNA/RNA Mini Kit (Qiagen #80204). A 506 base-pair
fragment was ampliﬁed by PCR using Supermix High Fidelity
Polymerase (Invitrogen #10790-020), forward primer 5′-GTT TCC
TTT TCT AGG CTA AGA ATG TTC TCC-3′ and reverse primer 5′-CAC
TTC CAG CCA CCC TCC-3′. PCR products were sequenced directly
using the forward primer. Chromatogram analysis was carried out
using Sequencher software (Gene Codes). Work with primate
materials was conducted at UT Austin under an approved biosafety
protocol (#2008-03-0049).Acknowledgments
We thank Drs. Greg Wilkerson and Welkin Johnson for provid-
ing rhesus macaque samples and the NIH AIDS Research and
R.M. McDougle et al. / Virology 441 (2013) 31–3938Reference Reagent Program for materials. This research was
funded by NIH R01 AI064046 and P01 GM091743 to RSH and
NIH R01 GM093086 to SLS. JFH was supported in part by a UMN
Graduate Student Fellowship. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
References
Albin, J.S., LaRue, R.S., Weaver, J.A., Brown, W.L., Shindo, K., Harjes, E., Matsuo, H.,
Harris, R.S., 2010. A single amino acid in human APOBEC3F alters susceptibility
to HIV-1 Vif. J. Biol. Chem. 285 (52), 40785–40792.
Bishop, K.N., Holmes, R.K., Sheehy, A.M., Davidson, N.O., Cho, S.J., Malim, M.H., 2004.
Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol.
14 (15), 1392–1396.
Bogerd, H.P., Doehle, B.P., Wiegand, H.L., Cullen, B.R., 2004. A single amino acid
difference in the host APOBEC3G protein controls the primate species speciﬁ-
city of HIV type 1 virion infectivity factor. Proc. Nat. Acad. Sci. U.S.A. 101 (11),
3770–3774.
Bogerd, H.P., Wiegand, H.L., Doehle, B.P., Lueders, K.K., Cullen, B.R., 2006a.
APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon func-
tion in human cells. Nucleic Acids Res. 34 (1), 89–95.
Bogerd, H.P., Wiegand, H.L., Hulme, A.E., Garcia-Perez, J.L., O'Shea, K.S., Moran, J.V.,
Cullen, B.R., 2006b. Cellular inhibitors of long interspersed element 1 and Alu
retrotransposition. Proc. Nat. Acad. Sci. U.S.A. 103 (23), 8780–8785.
Bogerd, H.P., Wiegand, H.L., Doehle, B.P., Cullen, B.R., 2007. The intrinsic antire-
troviral factor APOBEC3B contains two enzymatically active cytidine deaminase
domains. Virology 364 (2), 486–493.
Bulliard, Y., Narvaiza, I., Bertero, A., Peddi, S., Rohrig, U.F., Ortiz, M., Zoete, V., Castro-
Diaz, N., Turelli, P., Telenti, A., Michielin, O., Weitzman, M.D., Trono, D., 2011.
Structure-function analyses point to a polynucleotide-accommodating groove
essential for APOBEC3A restriction activities. J. Virol. 85 (4), 1765–1776.
Burns, M.B., Lackey, L., Carpenter, M.A., Rathore, A., Land, A.M., Leonard, B.,
Refsland, E.W., Kotandeniya, D., Tretyakova, N., Nikas, J.B., Yee, D., Temiz, N.A.,
Donohue, D.E., McDougle, R.M., Brown, W.L., Law, E.K., Harris, R.S., 2013.
APOBEC3B is an enzymatic source of mutation in breast cancer. Nature, http:
//dx.doi.org/10.1038/nature11881, February 6th, advance online publication.
Carpenter, M.A., Rajagurubandara, E., Wijesinghe, P., Bhagwat, A.S., 2010. Determi-
nants of sequence-speciﬁcity within human AID and APOBEC3G. DNA Repair
(Amst) 9 (5), 579–587.
Carpenter, M.A., Li, M., Rathore, A., Lackey, L., Law, E.K., Land, A.M., Leonard, B.,
Shandilya, S.M., Bohn, M.F., Schiffer, C.A., Brown, W.L., Harris, R.S., 2012. Methyl-
and normal-cytosine deamination by the foreign DNA restriction enzyme
APOBEC3A. J. Biol. Chem. 287 (41), 34801–34808.
Chen, H., Lilley, C.E., Yu, Q., Lee, D.V., Chou, J., Narvaiza, I., Landau, N.R., Weitzman,
M.D., 2006. APOBEC3A is a potent inhibitor of adeno-associated virus and
retrotransposons. Curr. Biol. 16 (5), 480–485.
Conticello, S.G., Thomas, C.J., Petersen-Mahrt, S.K., Neuberger, M.S., 2005. Evolution
of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol.
Biol. Evol. 22 (2), 367–377.
Dang, Y., Abudu, A., Son, S., Harjes, E., Spearman, P., Matsuo, H., Zheng, Y.H., 2011.
Identiﬁcation of a single amino acid required for APOBEC3 antiretroviral
cytidine deaminase activity. J. Virol. 85 (11), 5691–5695.
Doehle, B.P., Schafer, A., Cullen, B.R., 2005. Human APOBEC3B is a potent inhibitor
of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339 (2), 281–288.
Duggal, N.K., Malik, H.S., Emerman, M., 2011. The breadth of antiviral activity of
Apobec3DE in chimpanzees has been driven by positive selection. J Virol 85
(21), 11361–11371.
Esnault, C., Priet, S., Ribet, D., Heidmann, O., Heidmann, T., 2008. Restriction by
APOBEC3 proteins of endogenous retroviruses with an extracellular life cycle:
ex vivo effects and in vivo “traces” on the murine IAPE and human HERV-K
elements. Retrovirology 5, 75.
Gervaix, A., West, D., Leoni, L.M., Richman, D.D., Wong-Staal, F., Corbeil, J., 1997.
A new reporter cell line to monitor HIV infection and drug susceptibility
in vitro. Proc. Nat. Acad. Sci. U.S.A. 94 (9), 4653–4658.
Haché, G., Liddament, M.T., Harris, R.S., 2005. The retroviral hypermutation
speciﬁcity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA
cytosine deaminase domain. J. Biol. Chem. 280 (12), 10920–10924.
Haché, G., Shindo, K., Albin, J.S., Harris, R.S., 2008. Evolution of HIV-1 isolates that
use a novel Vif-independent mechanism to resist restriction by human
APOBEC3G. Curr. Biol. 18 (11), 819–824.
Hakata, Y., Landau, N.R., 2006. Reversed functional organization of mouse and
human APOBEC3 cytidine deaminase domains. J Biol Chem 281 (48),
36624–36631.
Harris, R.S., Hultquist, J.F., Evans, D.T., 2012. The restriction factors of human
immunodeﬁciency virus. J. Biol. Chem..
Hultquist, J.F., Lengyel, J.A., Refsland, E.W., LaRue, R.S., Lackey, L., Brown, W.L.,
Harris, R.S., 2011. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and
APOBEC3H demonstrate a conserved capacity to restrict Vif-deﬁcient HIV-1.
J. Virol. 85 (21), 11220–11234.
Jónsson, S.R., Haché, G., Stenglein, M.D., Fahrenkrug, S.C., Andrésdóttir, V., Harris, R.S.,
2006. Evolutionarily conserved and non-conserved retrovirus restriction activities of
artiodactyl APOBEC3F proteins. Nucleic Acids Res. 34 (19), 5683–5694.Kidd, J.M., Newman, T.L., Tuzun, E., Kaul, R., Eichler, E.E., 2007. Population
stratiﬁcation of a common APOBEC gene deletion polymorphism. PLoS Genet.
3 (4), e63.
Kinomoto, M., Kanno, T., Shimura, M., Ishizaka, Y., Kojima, A., Kurata, T., Sata, T.,
Tokunaga, K., 2007. All APOBEC3 family proteins differentially inhibit LINE-1
retrotransposition. Nucleic Acids Res. 35 (9), 2955–2964.
Kohli, R.M., Abrams, S.R., Gajula, K.S., Maul, R.W., Gearhart, P.J., Stivers, J.T., 2009.
A portable hot spot recognition loop transfers sequence preferences from
APOBEC family members to activation-induced cytidine deaminase. J. Biol.
Chem. 284 (34), 22898–22904.
LaRue, R.S., Jónsson, S.R., Silverstein, K.A., Lajoie, M., Bertrand, D., El-Mabrouk, N.,
Hötzel, I., Andrésdóttir, V., Smith, T.P., Harris, R.S., 2008. The artiodactyl
APOBEC3 innate immune repertoire shows evidence for a multi-functional
domain organization that existed in the ancestor of placental mammals. BMC
Mol. Biol. 9, 104.
LaRue, R.S., Andrésdóttir, V., Blanchard, Y., Conticello, S.G., Derse, D., Emerman, M.,
Greene, W.C., Jónsson, S.R., Landau, N.R., Löchelt, M., Malik, H.S., Malim, M.H.,
Münk, C., O'Brien, S.J., Pathak, V.K., Strebel, K., Wain-Hobson, S., Yu, X.F., Yuhki, N.,
Harris, R.S., 2009. Guidelines for naming nonprimate APOBEC3 genes and
proteins. J. Virol. 83 (2), 494–497.
Lackey, L., Demorest, Z.L., Land, A.M., Hultquist, J.F., Brown, W.L., Harris, R.S., 2012.
APOBEC3B and AID have similar nuclear import mechanisms. J. Mol. Biol. 419
(5), 301–314.
Li, M., Shandilya, S.M., Carpenter, M.A., Rathore, A., Brown, W.L., Perkins, A.L., Harki, D.A.,
Solberg, J., Hook, D.J., Pandey, K.K., Parniak, M.A., Johnson, J.R., Krogan, N.J.,
Somasundaran, M., Ali, A., Schiffer, C.A., Harris, R.S., 2011. First-in-class small
molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS
Chem. Biol. 7 (3), 506–517.
Love, R.P., Xu, H., Chelico, L., 2012. Biochemical analysis of hypermutation by the
deoxycytidine deaminase APOBEC3A. J. Biol. Chem. 287 (36), 30812–30822.
Malim, M.H., Emerman, M., 2008. HIV-1 accessory proteins—ensuring viral survival
in a hostile environment. Cell Host Microb. 3 (6), 388–398.
Mangeat, B., Turelli, P., Liao, S., Trono, D., 2004. A single amino acid determinant
governs the species-speciﬁc sensitivity of APOBEC3G to Vif action. J. Biol. Chem.
279 (15), 14481–14483.
Miyagi, E., Opi, S., Takeuchi, H., Khan, M., Goila-Gaur, R., Kao, S., Strebel, K., 2007.
Enzymatically active APOBEC3G is required for efﬁcient inhibition of human
immunodeﬁciency virus type 1. J. Virol. 81 (24), 13346–13353.
Muckenfuss, H., Hamdorf, M., Held, U., Perkovic, M., Lower, J., Cichutek, K., Flory, E.,
Schumann, G.G., Münk, C., 2006. APOBEC3 proteins inhibit human LINE-1
retrotransposition. J. Biol. Chem. 281 (31), 22161–22172.
Münk, C., Willemsen, A., Bravo, I.G., 2012. An ancient history of gene duplications,
fusions and losses in the evolution of APOBEC3 mutators in mammals. BMC
Evol. Biol. 12, 71.
Navarro, F., Bollman, B., Chen, H., Konig, R., Yu, Q., Chiles, K., Landau, N.R., 2005.
Complementary function of the two catalytic domains of APOBEC3G. Virology
333 (2), 374–386.
Olson, M.E., Li, M., Harris, R.S., Harki, D.A., 2013. Small-molecule APOBEC3G DNA
cytosine deaminase inhibitors based on a 4-amino-1,2,4-triazole-3-thiol scaf-
fold. Chem. Med. Chem. 8 (1), 112–117.
Rausch, J.W., Chelico, L., Goodman, M.F., Le Grice, S.F., 2009. Dissecting APOBEC3G
substrate speciﬁcity by nucleoside analog interference. J. Biol. Chem. 284 (11),
7047–7058.
Refsland, E.W., Stenglein, M.D., Shindo, K., Albin, J.S., Brown, W.L., Harris, R.S., 2010.
Quantitative proﬁling of the full APOBEC3 mRNA repertoire in lymphocytes
and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38 (13),
4274–4284.
Refsland, E.W., Hultquist, J.F., Harris, R.S., 2012. Endogenous origins of HIV-1 G-to-A
hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS
Pathog. 8 (7), e1002800.
Rose, K.M., Marin, M., Kozak, S.L., Kabat, D., 2005. Regulated production and anti-
HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G. AIDS Res.
Hum. Retroviruses 21 (7), 611–619.
Sawyer, S.L., Emerman, M., Malik, H.S., 2004. Ancient adaptive evolution of the
primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2 (9), E275.
Schmitt, K., Guo, K., Algaier, M., Ruiz, A., Cheng, F., Qiu, J., Wissing, S., Santiago, M.L.,
Stephens, E.B., 2011. Differential virus restriction patterns of rhesus macaque and
human APOBEC3A: implications for lentivirus evolution. Virology 419 (1), 24–42.
Schrofelbauer, B., Chen, D., Landau, N.R., 2004. A single amino acid of APOBEC3G
controls its species-speciﬁc interaction with virion infectivity factor (Vif). Proc.
Nat. Acad. Sci. U.S.A. 101 (11), 3927–3932.
Schumacher, A.J., Haché, G., MacDuff, D.A., Brown, W.L., Harris, R.S., 2008. The DNA
deaminase activity of human APOBEC3G is required for Ty1, MusD, and human
immunodeﬁciency virus type 1 restriction. J. Virol. 82 (6), 2652–2660.
Shandilya, S.M., Nalam, M.N., Nalivaika, E.A., Gross, P.J., Valesano, J.C., Shindo, K.,
Li, M., Munson, M., Royer, W.E., Harjes, E., Kono, T., Matsuo, H., Harris, R.S.,
Somasundaran, M., Schiffer, C.A., 2010. Crystal structure of the APOBEC3G catalytic
domain reveals potential oligomerization interfaces. Structure 18 (1), 28–38.
Stenglein, M.D., Harris, R.S., 2006. APOBEC3B and APOBEC3F inhibit L1 retro-
transposition by a DNA deamination-independent mechanism. J. Biol. Chem.
281 (25), 16837–16841.
Stenglein, M.D., Burns, M.B., Li, M., Lengyel, J., Harris, R.S., 2010. APOBEC3 proteins
mediate the clearance of foreign DNA from human cells. Nat. Struct. Mol. Biol.
17 (2), 222–229.
Thielen, B.K., McNevin, J.P., McElrath, M.J., Hunt, B.V., Klein, K.C., Lingappa, J.R., 2010.
Innate immune signaling induces high levels of TC-speciﬁc deaminase activity
R.M. McDougle et al. / Virology 441 (2013) 31–39 39in primary monocyte-derived cells through expression of APOBEC3A isoforms.
J. Biol. Chem. 285 (36), 27753–27766.
Virgen, C.A., Hatziioannou, T., 2007. Antiretroviral activity and Vif sensitivity of
rhesus macaque APOBEC3 proteins. J. Virol. 81 (24), 13932–13937.
Wang, M., Rada, C., Neuberger, M.S., 2010. Altering the spectrum of immunoglo-
bulin V gene somatic hypermutation by modifying the active site of AID. J. Exp.
Med. 207 (1), 141–153.
Wijesinghe, P., Bhagwat, A.S., 2012. Efﬁcient deamination of 5-methylcytosines in
DNA by human APOBEC3A, but not by AID or APOBEC3G. Nucleic Acids Res. 40
(18), 9206–9217.
Wissing, S., Montano, M., Garcia-Perez, J.L., Moran, J.V., Greene, W.C., 2011.
Endogenous APOBEC3B restricts LINE-1 retrotransposition in transformed cells
and human embryonic stem cells. J. Biol. Chem. 286 (42), 36427–36437.Xu, H., Svarovskaia, E.S., Barr, R., Zhang, Y., Khan, M.A., Strebel, K., Pathak, V.K.,
2004. A single amino acid substitution in human APOBEC3G antiretroviral
enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Proc. Nat. Acad. Sci. U.S.A. 101 (15), 5652–5657.
Yu, Q., Chen, D., Konig, R., Mariani, R., Unutmaz, D., Landau, N.R., 2004. APOBEC3B
and APOBEC3C are potent inhibitors of simian immunodeﬁciency virus replica-
tion. J. Biol. Chem. 279 (51), 53379–53386.
Zhang, J., Webb, D.M., 2004. Rapid evolution of primate antiviral enzyme APO-
BEC3G. Hum. Mol. Genet. 13 (16), 1785–1791.
Zhen,A.,Wang,T., Zhao,K.,Xiong,Y.,Yu,X.F., 2009.Asingleaminoaciddifference inhuman
APOBEC3H variants determines HIV-1 Vif sensitivity. J. Virol. 84 (4), 1902–1911.
